Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Andrew Zhu

Medical Oncology Boston, MA Medical Doctor

NPI 1699741769 CMS profile 348779

55 Fruit St, Yawkey 7E, Boston, MA 02114

Open in the dashboard

General payments

$207,403

153 records reported · program years 2019–2024

Research payments

$35,131

Paid to them · 37 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$484,831 paid to institutions, not to them · program years 2019–2022

Through program year 2024, Andrew Zhu of Boston, MA is reported in the CMS Open Payments database as having received $207,403 across 153 general payments and $35,131 in research payments paid to them. Separately, studies naming them as principal investigator received $484,831 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 Research $2,478 2
2022 General $4,400 3
2022 Research $1,389 2
2021 General $39,117 15
2021 Research $6,780 7
2020 General $42,411 18
2020 Research $24,484 26
2019 General $121,476 117

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Zhu
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Andrew Zhu were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Andrew Zhu Medical Oncology median Middle half National median
2019 $121,476 $968 $140–$6,658 $163
2020 $42,411 $747 $102–$5,891 $114
2021 $39,117 $430 $50–$4,098 $132
2022 $4,400 $812 $127–$4,907 $149
2023 $0 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $0 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Merck Sharp & Dohme Corporation $52,276 45 payments
  2. Eli Lilly and Company $23,757 11 payments
  3. F. Hoffmann-La Roche AG $23,703 15 payments
  4. Eisai Co., Ltd. $18,915 6 payments
  5. Exelixis Inc. $16,315 12 payments
  6. Eisai Inc. $14,258 14 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $12,114 17 payments
  8. Novocure Inc. $7,800 2 payments
  9. Sirtex Medical Inc $7,083 4 payments
  10. Sanofi US Services Inc. $6,680 7 payments
  11. Other $24,501 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $132,072 44 payments
  2. Travel and Lodging $39,637 48 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,667 4 payments
  4. Honoraria $8,750 2 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $4,023 2 payments
  6. Food and Beverage $2,943 52 payments
  7. Education $312 1 payment
Products named General payments · program years 2019–2024
  1. Lenvima Oncology $33,173 20 payments
  2. TECENTRIQ $20,599 14 payments
  3. Avastin $15,774 8 payments
  4. Nexavar $12,114 17 payments
  5. CYRAMZA $11,507 9 payments
  6. KEYTRUDA $9,254 10 payments
  7. SIR-Spheres Microspheres $7,083 4 payments
  8. NO PRODUCT DISCUSSED $6,680 7 payments
  9. LENVIMA Oncology $5,043 6 payments
  10. TIBSOVO $4,058 3 payments
  11. Other $4,060 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. F. Hoffmann-La Roche AG $35,131 37 payments

Records

190 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record